EN DE
STOCK COMPARISON

Broncus Holding vs Abbott Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how Broncus Holding (2216) and Abbott Laboratories (ABT) compare, as of Oct 1, 2026.

As of Oct 1, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Broncus Holding trades at HK$0.74 versus a fair value of HK$0.28 (−61.9%), while Abbott Laboratories trades at $98.83 versus $74.79 (−24.3%).
Broncus Holding
2216.HK · HKD · Health Care
−61.9%
upside to fair value
overvalued
PriceHK$0.74
Fair ValueHK$0.28
Quality40/100
Abbott Laboratories
ABT · USD · Health Care
−24.3%
upside to fair value
overvalued
Price$98.83
Fair Value$74.79
Quality66/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Broncus HoldingAbbott Laboratories
Valuation
n/aP/E (TTM)32.7×
n/aForward P/E (FY2027)16.3×
n/aMedian P/E at FY-end (9 FY, ex one-offs where documented)33.6×
n/aP/S (TTM)3.70×
0.30×P/B3.30×
n/aEV/EBITDA14.9×
n/aPEG1.90×
−61.9%Fair value upside−24.3%
n/aDividend yield2.5%
n/aDividend per share$2.48
Profitability
n/aOperating margin14.7%
n/aEBIT margin trend (5Y)1.19×
-11.2%Return on equity10.6%
-9.2%Return on assets5.3%
Growth
-55.4%Revenue growth (YoY)13.0%
-73.6%Avg. growth/yr (3Y)0.5%
-44.3%Avg. growth/yr (5Y)5.1%
n/aValue creation/yr+10.7%
Balance & size
n/aInterest coverage (EBIT/interest)23.6×
n/aDebt / equity0.19×
$45MMarket cap$172B
weakGrowth qualityhealthy
Abbott Laboratories, median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2016, FY2020 ex one-offs: 33.6.
Forward P/E: price divided by the analyst consensus for the first fiscal year that has not started yet. The current year carries special items from quarters already reported.

Abbott Laboratories leads: 1 to 5 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Broncus Holdingof which business quality 40 · market factors 16 Abbott Laboratoriesof which business quality 66 · market factors 47
ProfitabilityMargins and returns on capital today
0
50
Quality GrowthAre margins and returns improving?
10
47
CashflowEarnings quality: real cash, not paper profit
1
71
Fin. StrengthBalance sheet, leverage, solvency risk
92
80
InvestmentDisciplined investing over empire-building
69
65
Low VolatilityCalm price path (market factor)
25
84
MomentumPrice trend over the last 3–12 months (market factor)
18
38
52W MomentumDistance to the 52-week high (market factor)
3
20
Net IssuanceShare count: buybacks or dilution?
88
83

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyBroncus HoldingPrice HK$0.74Abbott LaboratoriesPrice $98.83
DCF Modelsn/a−24.3%below the price$74.80
Earnings-Basedn/a−70.2%below the price$29.42
Dividend Discountn/a−59.8%below the price$39.73
Multiplesn/a−28.4%below the price$70.72
Asset-Based−70.1%below the priceHK$0.22−79.7%below the price$20.05
Growth DCFn/a−30.6%below the price$68.58
Economic Profitn/a−62.1%below the price$37.49
Growth Earningsn/a−28.9%below the price$70.25
Minimum−70.1%below the priceHK$0.22−79.7%below the price$20.05
Maximum−70.1%below the priceHK$0.22−24.3%below the price$74.80
Median−70.1%below the priceHK$0.22−45.2%below the price$54.15
Geometric mean−70.1%below the priceHK$0.22−52.8%below the price$46.64

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Broncus Holding: 1 of 1 models see the stock below the current price.

Abbott Laboratories: 26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Broncus Holding
Price HK$0.74
Fair Value HK$0.28
Bear HK$0.19Bull HK$0.36
Abbott Laboratories
Price $98.83
Fair Value $74.79
Bear $52.28Bull $94.43

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Broncus Holding · Health Care

Quality score40 · below median
Fair value upside−61.9% · bottom 25%

Abbott Laboratories · Health Care

Quality score66 · Top 25%
Fair value upside−24.3% · below median

Bottom line

As of Oct 1, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Broncus Holding trades at HK$0.74 versus a fair value of HK$0.28 (−61.9%), while Abbott Laboratories trades at $98.83 versus $74.79 (−24.3%).

Abbott Laboratories has the higher quality score (66/100).

Open Abbott Laboratories live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.